Eledon Pharmaceuticals (FRA:2TK) COGS-to-Revenue : 0.00 (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals COGS-to-Revenue?

Eledon Pharmaceuticals's Cost of Goods Sold for the three months ended in Jun. 2024 was €0.00 Mil. Its Revenue for the three months ended in Jun. 2024 was €0.00 Mil.

Eledon Pharmaceuticals's COGS to Revenue for the three months ended in Jun. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Eledon Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2024 was N/A%.

Eledon Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Eledon Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals COGS-to-Revenue Chart

Eledon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Eledon Pharmaceuticals Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Eledon Pharmaceuticals COGS-to-Revenue Calculation

Eledon Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Eledon Pharmaceuticals's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Eledon Pharmaceuticals (FRA:2TK) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Eledon Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Eledon Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Eledon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ELDN:USA

Address

19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612

Website

https://www.eledon.com

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals Headlines

No Headlines